null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

Icatolimab Biosimilar (Anti-BTLA) Antibody (HDBS0053)

SKU HDBS0053
Antibody Type Biosimilar Reference Antibody
Applications IHC
Applications FC
Applications Drug Development
Applications Pharmacokinetics
Disease Area Cancer
Protein BTLA
Reactivity Human
Host Species Chimeric Humanized
Isotype IgG4
€431
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

Icatolimab (Anti-BTLA) Biosimilar Antibody (HDBS0053)

The Anti-BTLA (ICAToli Biosimilar) Antibody (HDBS0053) is a high-quality research tool designed for studying BTLA, a co-inhibitory immune checkpoint receptor involved in the regulation of immune responses. This antibody, produced through a biosimilar process, exhibits high reactivity with human samples and is validated for use in various immunological assays, including Western blotting.BTLA, or B and T lymphocyte attenuator, plays a pivotal role in modulating immune responses by suppressing T cell activation and cytokine production. Dysregulation of BTLA signaling has been implicated in various diseases, including cancer and autoimmune disorders, making it a promising target for therapeutic intervention.

Research on BTLA function and signaling pathways is crucial for developing novel immunotherapies and understanding immune system dysregulation in disease settings.Overall, the Anti-BTLA (ICAToli Biosimilar) Antibody (HDBS0053) serves as a valuable tool for investigating the role of BTLA in immune regulation and disease pathogenesis, providing new insights into potential therapeutic strategies for immune-related disorders.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose